Retinal disease drugs
These companies develop drugs for retinal diseases such as macular degeneration.
+39.9%
over 1 year · S&P 500 +11.6%
Key indicators
Health
48 / 100
Fragile
Solid
Price
P/E 17
Cheap
Expensive
Up over 1 year
9 of 14
Volatility
77%
Calm
Choppy
Health and price: against the other tags.
Key indicators
When a figure has a bar, the marker places it among its peers, and the further right it sits, the more the figure beats the others. Green marks the best third, red the weakest and white anything in between. Some figures stay white wherever they sit, like price, pace or holding time, because neither side is better there.
The 14 companies
REGN
+40.9%
Size: weight in the tag. Color: move over the period.
See all companies
See all companies
R
Regeneron Pharmaceuticals
REGN
82.2%
+40.9%
K
Kodiak Sciences
KOD
6.0%
+449.1%
B
Belite Bio
BLTE
5.5%
+48.3%
A
ANI Pharmaceuticals
ANIP
1.4%
−18.1%
O
Ocular Therapeutix
OCUL
1.3%
−46.0%
M
MeiraGTx Holdings
MGTX
0.8%
+6.0%
A
Annexon
ANNX
0.7%
+38.0%
F
4D Molecular Therapeutics
FDMT
0.6%
+11.5%
S
Surrozen
SRZN
0.5%
+144.3%
R
REGENXBIO
RGNX
0.5%
−34.1%
I
Opus Genetics
IRD
0.3%
+107.3%
B
BioAge Labs
BIOA
0.2%
−30.7%
E
EyePoint
EYPT
<0.1%
−97.4%
R
Roche Holdings
RHHBY
+21.9%